The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer
Abroad (travel likely)RecruitingPHASE2
Conditions
Colorectal Neoplasms · RAS · BRAF · Cetuximabβ · Fruquintinib
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Second Affiliated Hospital Zhejiang University College of Medicine, Hangzhou, Zhejiang Province 310999, Hangzhou, Zhejiang, China
Study leads
Kefeng Ding, PhD
Principal Investigator
Second Affiliated Hospital, School of Medicine, Zhejiang University